Ivacaftor is the first CFTR potentiator approved for patients ≥3 months old with at least one gating variation e.g., G551D class III, which is present in around 4% of the CF patient population (Ghelani and Schneider-Futschik, 2020). Here, CFTR is linked to cystic fibrosis.